Connetics Names Shari Geffon Senior Director, Project Management; Reports New Option Grant Under NASDAQ Marketplace Rule 4350
Posted on: Monday, 5 June 2006, 18:00 CDT
Connetics Corporation (NASDAQ:CNCT), a specialty pharmaceutical company that develops and commercializes dermatology products, announced today that it has named Shari Geffon to the position of Senior Director, Project Management.
Additionally, the Compensation Committee of the Company's Board of Directors approved an inducement grant to Ms. Geffon of a non-qualified stock option to purchase 20,000 shares of Connetics' common stock. This option award was granted without stockholder approval pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv) and with the following material terms: (a) an exercise price of $12.11 which is equal to the fair market value of Connetics' common stock on the grant date (June 5, 2006), (b) a term of 10 years, and (c) a vesting schedule providing that the option is exercisable as to 1/8th of the total grant on the six-month anniversary of Ms. Geffon's hire, and 1/48th of the total grant each month thereafter until each grant is fully vested.
About Connetics
Connetics Corporation is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market. Connetics has branded its proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone valerate) Foam, 0.12%, Soriatane(R) (acitretin) capsules and Evoclin(R) (clindamycin) Foam, 1%. Connetics is developing Desilux(TM) (desonide) VersaFoam-EF, 0.05%, a low-potency topical steroid formulated to treat atopic dermatitis; Primolux(TM) (clobetasol propionate) VersaFoam-EF, 0.05%, a super high-potency topical steroid formulation to treat atopic dermatitis and plaque psoriasis; Extina(R) (ketoconazole) VersaFoam-HF, 2%, to treat seborrheic dermatitis and Velac(R) (a combination of 1% clindamycin and 0.025% tretinoin) Gel, for treating acne. Connetics' product formulations are designed to improve the management of dermatological diseases and provide significant product differentiation. In Connetics' marketed products, these formulations have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance. For more information about Connetics and its products, please visit www.connetics.com.
Press Release Code: (CNCT-G)
Source: Business Wire
Related Articles
- Standard Motor Products, Inc. Announces Common Stock Offering
- Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal
- Synthesis Energy Systems Announces Closing of Over-Allotment Option for Common Stock Offering
- GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to Taxanes
- Acusphere Shareholders Grant Board the Discretion to Effect Reverse Stock Split
- Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
- Metabasis Announces European Commission Grants Orphan Medicinal Product Designation to MB07133, Its Product Candidate for the Treatment of Primary Liver Cancer
- European Commission Grants Orphan Medicinal Product Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for the Prevention of Pulmonary Fungal Infections in Patients Deemed At Risk
- European Commission Grants Orphan Medicinal Product Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
- US Government $20M NIAID Grant Funds Proteome Systems' ''Catalytic Scavenger Compounds'' to Treat Radiation Damage in Humans Caused By Terrorist Attacks or Industrial Accidents; PSL Invited to Present at Prestigious BIO Investor Forum
 |
 |
User Comments (0)
RSS Feeds